With a shortage of new tuberculosis drugs in the pipeline, a software tool from the University of Michigan can predict how current drugs–including unlikely candidates–can be combined in new ways to create more effective treatments.
“This could replace our traditional trial-and-error system for drug development that is comparatively slow and expensive.” Sriram Chandrasekaran, U-M assistant professor of biomedical engineering, who leads the research.
